This company and stock is great at these valuations. MM wanted to drive down the price which it might do again. I'm just riding it out with the MM/institutions. BNGO has over $300 mil in cash with revenues increasing year over year. Inflation really is not much of an issue because of the cash on hand. Bio-discovery lines up BNGO to be integrated with Sequencing companies such as Illumina. Saphyre keeps improving and BNGO it self evolving and being adopted more and more. Next up should be streamlining the process for the customers to bill insurance for using Saphyre which they have done previously with teaching hospitals. CMS now has a code to bill private ins which will speed up adoption of a great tech
M
Ok if you can’t see the manipulation that has been occurring to this stock based on todays trading then you should stop owning stocks! This stock has needed to trade over 10m with massive short selling to drive the price down 10pm more cents. Today no one is shorting stocks and as such the volume is only 3m shares so far and the stock has gone up 30 cents. What do you think happens when 40 m shares need to cover? Oh and for all you shorts that keep pointing to revenue and valuations pacb has under 70m in revenue and a market cap over 4 b. Bngo will be at that level in two years from now and so the stock is an easy triple in that timeframe
T
If PPS continues upward, will provide a whole lot of trapped short sellers waiting to get cover and fear/margin call driven liquidators waiting to get back in, chasing PPS ever higher. We shall see.
V
Bionano Genomics, Inc. (NASDAQ:BNGO) Number of Hedge Fund Holders: 14
Bionano Genomics, Inc. (NASDAQ:BNGO) is a genome analysis company. The journalist investor gave the firm a Sell rating during the Lightning Round of his show on November 29.
Bionano Genomics, Inc. (NASDAQ:BNGO) has a market cap of over $1 billion and posted $8.5 million in revenue last year. The short interest on the stock is over 13% and it is one of the most high volume names on the market.
At the end of the third quarter of 2021, 14 hedge funds in the database of Insider Monkey held stakes worth $13 million in Bionano Genomics, Inc. (NASDAQ:BNGO), down from 17 the preceding quarter worth $40 million. I will be buying this stock this is a steal....go bngo
M
Seriously? Cramer makes a "bear" call after BNGO drops from $15 to $4. Go Cramer!
e
BNGO has well over 300million cash in the bank which is like 10 percent less than the IPO. BNGO has no debt which is huge! That's why insiders are buying. The stock is being shorted manipulated and tax sold. This is a top-notch life science company. Don't listen to the shorts who spread FUD... I added another 1000shares today. When sp gets to $200 in a few years, you will regret not buying at this fire sale.
g
BNGO a True Bargain at these prices......$6+ qnd higher coming hold onto your shares
M
Yesterday I wrote the following message (see below), hope this becomes true :-)!
Last year we start increasing on Dec 23 2020, we open 0.57 and close 0.78! Hope this year we start tomorrow with increasing…
A
What's a few hundred thousand lost among friends? The thing about this is, for all those claiming it will drive in a straight line to ZERO, there are others who understand the poential and see a recovery as imminent. I do not expect a magical check-mark that reverses and rises to the ether. I expect we will have a rough sideways time here leading into 2022. But I expect us to climb nicely next year. It is a compelling offering, a leader in its class...a company with plenty of cash, a great leadership team, and huge opportunities.
R
Who's shares have they gotten? They haven't got mine, that's for sure!!! In it for the long haul. I believe in this company! GO BNGO
P
The CEO is buying his own company's stock. I added more BNGO today. I also added NNDM and SWKS. My other undervalued stocks all are on file today: SIMO, ACLS, AOSL, COHU, ICHR, UCTT, IIVI, MU, WDC, HIMX.
D
A great time to accumalate an innovative young company, that is well funded and in the first inning.
R
Classic mega short Squeeze. Top of the First inning.
J
For all of you in doubt-growth stocks have been clobbered!Look at Illumina!Tax loss season is here so everything may drop more but we’re due for a good bounce.Earnings out in early Feb. and they should be the best yet.Expect higher revenues and the eps to still be negative but that’s the normal path of high growth companies.We’ll really ramp up next year!Keep the faith and buy the dip
J
Shorts need to cover and folks had better scramble to buy at this fire sale price
F
Price target is 12! It only needs to go up 400%! Lol
r
The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 12.00, with a high estimate of 14.00 and a low estimate of 10.00. The median estimate represents a +260.36% increase from the last price of 3.33.
C
Way oversold, there is nothing changed in the fundamentals of the company. Just one lowly analyst who has no credibility just gives a ba dating because of revenue, whereas other analysts are all bullish and people ignore them. Remember market looks forward and never looks back, otherwise all the growth company’s including TESLA would not be trading at these multiples. The guy is full of it and he wanted to buy shares for the company he works for at a discount. This company I’d forecasting growth of 50% for the foreseeable future. They have exceeded their goals every quarter. This analyst does not know what he is talking about and does not understand the the technology behind it. This company is a game changer. Give another quarter and two. As I said market looks ahead and not backward.
B
Cramer is buying at a bargain price. Wow!
T
Cramer opening his trap was probably the biggest signal to buy. LOL
Number of Hedge Fund Holders: 14
Bionano Genomics, Inc. (NASDAQ:BNGO) is a genome analysis company. The journalist investor gave the firm a Sell rating during the Lightning Round of his show on November 29.
Bionano Genomics, Inc. (NASDAQ:BNGO) has a market cap of over $1 billion and posted $8.5 million in revenue last year. The short interest on the stock is over 13% and it is one of the most high volume names on the market.
At the end of the third quarter of 2021, 14 hedge funds in the database of Insider Monkey held stakes worth $13 million in Bionano Genomics, Inc. (NASDAQ:BNGO), down from 17 the preceding quarter worth $40 million. I will be buying this stock this is a steal....go bngo
Last year we start increasing on
Dec 23 2020, we open 0.57 and close 0.78!
Hope this year we start tomorrow with increasing…
short Squeeze.
Top of the First inning.